DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for alopecia areata — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlopecia areata maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alopecia areata is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BMX non-receptor tyrosine kinase (BMX) — BMX is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8X2A · 1.3 Å · ligand 4-[(3S)-3-{[(2E)-but-2-enoyl]amino}piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide (LTJ). Experimental structure, not a prediction.
What the evidence adds up to
Alopecia areata is understood as an inflammatory, probably autoimmune, disease mediated predominantly by CD8+ lymphocytes, with the disease mechanism driven by CD4+ lymphocytes. Genetic susceptibility contributes to development, but onset and presentation are modified by complex environmental interplay. The pathogenetic mechanism is described as particularly robust, and the development of a cure is considered a significant challenge.
In a 1996 study of 1996, serum cytokine profiles differed between the localised form and the extensive form (alopecia universalis). Patients with localised disease had significantly elevated serum levels of interleukin 1 alpha and interleukin 4, consistent with a Th2 cytokine response. Patients with the extensive form had significantly elevated serum levels of interferon gamma and interleukin 2, consistent with a Th1 cytokine response.
A 2011 review states that many therapeutic modalities have been used, with variable efficacy and safety profiles, but none is curative or preventive. Many agents have not been subjected to randomised controlled trials, and except for topical immunotherapy, few published studies on long-term outcomes exist. A 2006 review notes that on the basis of current understanding of pathogenesis, several experimental and theoretical therapeutic approaches might be possible, but does not report any tested intervention.
What is still missing are randomised controlled trials for most proposed treatments, long-term outcome data beyond topical immunotherapy, and any intervention that has demonstrated curative or preventive effect in a controlled setting. Patient stratification by cytokine profile or disease extent has not been used to guide treatment selection in a prospective trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Reviews in Molecular Medicine · 2006 · 163 citations
Alopecia areata: pathogenesis and potential for therapy
AbstractAlthough the complete picture for alopecia areata (AA) pathogenesis has yet to be determined, recent research has made much progress in our understanding of the disease mechanism. Numerous circumstantial evidence supports the notion that AA is fundamentally a disease mediated by inflammatory cells and may be autoimmune in nature. Recent research has shown the hair-loss phenotype is precipitated predominantly by CD8+ lymphocytes, but the disease mechanism is driven by CD4+ lymphocytes. Although genetic susceptibility is a key contributor to disease development, disease onset and phenotypic presentation are probably modified by complex environmental interplay. On the basis of our current understanding of AA disease pathogenesis, several experimental and theoretical therapeutic approaches might be possible. However, the pathogenetic disease mechanism is particularly robust and the development of a cure for AA will be a significant challenge.
Clinical Cosmetic and Investigational Dermatology · 2011 · 100 citations · open access
Alopecia areata: a new treatment plan
AbstractMany therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes. The treatment plan is designed according to the patient's age and extent of disease. In this paper, the therapeutic agents are organized according to their efficacy and safety profiles into first-line, second-line, and third-line options.
Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis).
AbstractRecent studies have suggested that cytokines play a critical role in the pathophysiology of alopecia areata; however, no information is available regarding the difference in cytokine profiles in these patients. Serum levels of cytokines, including interferon gamma (IFN-gamma), tumor necrosis factor alpha, interleukin 1 alpha (IL-1 alpha), IL-2, IL-4, and IL-6, were measured using radioimmunoassay or enzyme-linked immunosorbent assay techniques in patients with the localized form and the extensive form (alopecia universalis). The serum levels of IL-1 alpha and IL-4 were significantly elevated in patients with the localized form. In contrast, the serum levels of IFN-gamma and IL-2 were significantly elevated in patients with the extensive form. These results indicate that immune responses in the localized form and the extensive form of alopecia areata are regulated by Th2 cytokines and Th1 cytokines, respectively.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
